Cervical cancer is the most common malignant tumor among women in developing countries, and its incidence ranks first among malignant tumors of female genital organs. Cervical cancer can occur in women of any age, but the focus of screening should be on the age group of 30 to 70 years old. It is internationally recognized that cervical cancer screening and treatment is an important measure to reduce the incidence and mortality of cervical cancer. TCT examination is the most advanced cervical cancer cytological examination technique in the world, which significantly improves the satisfaction of the specimen and the detection rate of abnormal cervical cells compared with the traditional Pap smear, and can also detect precancerous lesions and microbial infections such as mycobacteria, trichomonas, chlamydia, etc. as early as possible. HPV testing refers to the detection of human papillomavirus. Certain subtypes of HPV infection are strongly associated with the development of cervical cancer. This screening technique is important for detecting HPV high-risk subtypes and predicting the risk of disease occurrence and lesion development. The screening of people with cervical disease is conducive to early detection, early diagnosis and early treatment of cervical disease.